Chi­nese biotech Biokin said its EGFRx­HER3 bis­pe­cif­ic an­ti­body-drug con­ju­gate passed a late-stage Chi­na tri­al in a ge­net­i­cal­ly-de­fined form of lung can­cer, buoy­ing op­ti­mism for a …

Endpoints News
Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.